Julius Chapiro1, Rafael Duran2, MingDe Lin3, Benedetto Mungo4, Todd Schlachter2, Rüdiger Schernthaner2, Boris Gorodetski1, Zhijun Wang2, Jean François Geschwind5. 1. Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Sheikh Zayed Tower, Suite 7203, 1800 Orleans St, Baltimore, MD, USA 21287; Department of Diagnostic and Interventional Radiology, Charite Universitätsmedizin, Berlin, Germany. 2. Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Sheikh Zayed Tower, Suite 7203, 1800 Orleans St, Baltimore, MD, USA 21287. 3. U/S Imaging and Interventions (UII), Philips Research North America, Briarcliff Manor, NY, USA. 4. Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA. 5. Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Sheikh Zayed Tower, Suite 7203, 1800 Orleans St, Baltimore, MD, USA 21287. Electronic address: jfg@jhmi.edu.
Abstract
BACKGROUND: The clinical management of patients with metastatic soft-tissue sarcoma of the liver is complicated by the paucity of reliable clinical data. This study evaluated the safety profile, survival outcome as well as the role of imaging biomarkers of tumor response in metastatic soft-tissue sarcoma (mSTS) of the liver treated with conventional transarterial chemoembolization (cTACE). MATERIALS/ METHODS: This retrospective analysis included 30 patients with mSTS of the liver treated with cTACE. The safety profile, overall survival (OS) and progression-free survival (PFS) after the procedure were evaluated. Tumor response in each patient was assessed using RECIST, modified (m) RECIST and EASL guidelines. In addition, a 3D quantification of the enhancing tumor volume (quantitative [q] EASL) was performed. For each method, patients were classified as responders (R) and non-responders (NR), and evaluated using Kaplan-Meier and multivariate Cox proportional hazard ratio (HR) analysis. RESULTS: No Grade III or IV toxicities were reported in a total of 77 procedures (mean, 2.6/patient). Median OS was 21.2 months (95% CI, 13.4-28.9) and PFS was 6.3 months (95% CI, 4.4-8.2). The enhancement-based techniques identified 11 (44%), 12 (48%) and 12 (48%) patients as R according to EASL, mRECIST and qEASL, respectively. No stratification was achieved with RECIST. Multivariate analysis identified tumor response according to mRECIST and qEASL as reliable predictors of improved patient survival (P=0.019; HR 0.3 [0.1-0.8] and P=0.006; HR 0.2 [0.1-0.6], respectively). CONCLUSION: This study confirmed the role of cTACE as a safe salvage therapy option in patients with mSTS of the liver. The demonstrated advantages of enhancement-based tumor response assessment techniques over size-based criteria validate mRECIST and qEASL as preferable methods after intraarterial therapy.
BACKGROUND: The clinical management of patients with metastatic soft-tissue sarcoma of the liver is complicated by the paucity of reliable clinical data. This study evaluated the safety profile, survival outcome as well as the role of imaging biomarkers of tumor response in metastatic soft-tissue sarcoma (mSTS) of the liver treated with conventional transarterial chemoembolization (cTACE). MATERIALS/ METHODS: This retrospective analysis included 30 patients with mSTS of the liver treated with cTACE. The safety profile, overall survival (OS) and progression-free survival (PFS) after the procedure were evaluated. Tumor response in each patient was assessed using RECIST, modified (m) RECIST and EASL guidelines. In addition, a 3D quantification of the enhancing tumor volume (quantitative [q] EASL) was performed. For each method, patients were classified as responders (R) and non-responders (NR), and evaluated using Kaplan-Meier and multivariate Cox proportional hazard ratio (HR) analysis. RESULTS: No Grade III or IV toxicities were reported in a total of 77 procedures (mean, 2.6/patient). Median OS was 21.2 months (95% CI, 13.4-28.9) and PFS was 6.3 months (95% CI, 4.4-8.2). The enhancement-based techniques identified 11 (44%), 12 (48%) and 12 (48%) patients as R according to EASL, mRECIST and qEASL, respectively. No stratification was achieved with RECIST. Multivariate analysis identified tumor response according to mRECIST and qEASL as reliable predictors of improved patient survival (P=0.019; HR 0.3 [0.1-0.8] and P=0.006; HR 0.2 [0.1-0.6], respectively). CONCLUSION: This study confirmed the role of cTACE as a safe salvage therapy option in patients with mSTS of the liver. The demonstrated advantages of enhancement-based tumor response assessment techniques over size-based criteria validate mRECIST and qEASL as preferable methods after intraarterial therapy.
Authors: Beom Kyung Kim; Seung Up Kim; Myeong-Jin Kim; Kyung Ah Kim; Do Young Kim; Jun Yong Park; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon Journal: Clin Cancer Res Date: 2012-12-07 Impact factor: 12.531
Authors: Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker Journal: Cancer Date: 2013-01-18 Impact factor: 6.860
Authors: Fernanda D Gonzalez-Guindalini; Marcos P F Botelho; Carla B Harmath; Kumaresan Sandrasegaran; Frank H Miller; Riad Salem; Vahid Yaghmai Journal: Radiographics Date: 2013-10 Impact factor: 5.333
Authors: Lukas M Nystrom; Nickolas B Reimer; John D Reith; Long Dang; Robert A Zlotecki; Mark T Scarborough; C Parker Gibbs Journal: ScientificWorldJournal Date: 2013-07-28
Authors: Susanne Smolka; Julius Chapiro; Wilfred Manzano; John Treilhard; Eric Reiner; Yanhong Deng; Yan Zhao; Bernd Hamm; James S Duncan; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind Journal: Clin Imaging Date: 2017-06-07 Impact factor: 1.605
Authors: Frederike A B Grimme; Maarten F J Seesing; Richard van Hillegersberg; Frits van Coevorden; Koert P de Jong; Iris D Nagtegaal; Cornelis Verhoef; Johannes H W de Wilt Journal: Dig Surg Date: 2018-09-25 Impact factor: 2.588